FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Docket Number 5405-252			Serial No. 10/008,062	
ł		OCUMENTS CITE							
0	IP	se several sheets if	necessary)	Applicants: David Rizzieri et al.					
MAD	o _	7C18		пррисаны.	DAVIO KIZZI				
MAR 0 7 2002 (S)					Filing Date October 19, 2001			Group	
TRAL	EMARY	" 	U. S	S. PATENT DO	CUMENTS				
Examiner Initial			Date	N	ame	Class	Subclass	Filing Date if Appropriate	
amh	1.	4.474.893	10/02/84	Reading		436	547	07/01/81	
	2.	4,676,980	06/30/87	Segal et al.		424	85	19/23/85	
	3.	4,816,567	03/28/89	Cabilly et al.		530	387	04/08/83	
V	4.	5,624,659	04/29/97	Bigner et al.		424	1.49	02/22/95	
		<u></u>				<u> </u>			
	,		FORE	IGN PATENT I	OCUMENTS		,		
		Document Number	untry	Class	Subclass	Translation Yes No			
	ļ			<u></u>					
			ļ						
	<u> </u>	l <u>.</u>	L	L		<u> </u>			
	1				, Title, Date, Pe				
anh	5.	Aeschlimann et al., Identification of Gln726 in nidogen as the amine acceptor in transglutarninase- catalyzed cross-linking of laminin-nidogen complexes, J Biol Chem., 267:11316-21 (1992).							
V	6.	Akabani et al., D	Posimetry of ¹³ s in patients w	¹ l-Labeled 81 C oith malignant b	6 monoclonal an rain tumors, J N	utibody admir lucl Med., 40	istered into s :631-638 (19	urgically created 99).	
amh	7.	Back et al., Tena Pathol (1996) 80				nd gastrointe	estinal tracts,	Verh Dtsch Ges	
amh	8.	Bell WR, The fib	orinolytic syste	em in neoplasia	Sem Throm He	mostat., 22:4	59-478 (1996).	
cunh	9.	Bigner et al., lod recurrent malign							
	10.	Birchall et al., A microcomputer algorithm for solving first-order compartmental involving recycling. Health Physics, 56:857-868 (1989).							
l V	11.	Bourdon et al., Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody, Cancer Res, 43:2796-2805 (1983).							

EXAMINER

INER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *EXAMINER

FORM PTO-		U.S. Department of Commerce ant and Trademark Office	Attorney Docket Number 5405-252	Serial No. 10/008,062				
LIST	OF DO	OCUMENTS CITED BY APPLICANT						
10	IPIZ	se several sheets if necessary)						
<i>\(\lambda_{\text{.}} \)</i>		Ke 18.	Applicants: David Rizzieri et al.					
MAR	C 7 2C	SI 💥	Filing Date October 19, 2001	Group				
THE POLICE OF TH	incat)	r [§]		1642				
um,	12.	Broll et al., Expression of tenascin in tumors (Pathol, 141:111-119 (1995).						
ann	13.	Bullard et al., In vivo imaging of intracranial nonspecific radiolabeled monoclonal antibod	human glioma xenografts comparing specifies, J Neurosurg 64:257-262 (1986).	fic with				
Amn.	14.	Bullard et al., Specific imaging of human brai antibodies (MAbs), Nuklearmedizin-Nuclear l	in tumor xenografts utilizing radiolabelled	monoclonal				
amh	15.	Folkman, J, Anti-angiogenesis: new concept f		:409-416				
amh	16.	Forsberg et al., Skin wounds and severed nerves heal normally in mice lacking tenascin-C, Proc Natl Acad Sci USA, 93:6594-6599 (1996).						
	17.		Harris et al., A revised European-American classification of lymphoid neoplasms: A proposal form the International Lymphoma Study Group, Blood:1361-1392 (1994).					
amh	18.	Harris et al., Growth factors and angiogenesis in breast cancer, Recent Results in Cancer Research, 127:35-41 (1993).						
V	19.	He et al., Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein Tenascin, J. Neuroimmunol., 52:127-137 (1994).						
inh	20.	Hettasch et al., Tissue transg lutaminase expression in human breast cancer. Lab. Invest., 75:637-645 (1996).						
anh	21.	Huse, M., Generationof a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda, Science, 246:1275-1281 (1989).						
amh	22.	Jahkola et al., Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis, Int J Cancer, 69:445-447 (1996).						
amh	23.	Jallo et al., Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis, Neurosurgery, 41:1052-1059 (1997).						
amh	24.	Kawakatsu et al., Human carcinoma cells synthesize and secrete tenascin in vitro, Jpn J Cancer Res. 83:1073-1080 (1992).						
am	25.	Kojima et al., Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells, J Cell Biol., 121:439-448 (1993).						
	26.	Kostianovsky et al., Tenascin-C expression in ultrastructurally defined angiogenic and vasculogenic lesions, Ultrastructural Pathol, 21:537-544 (1997).						
V	27.	Kusagawa et al., Expression and degradation of tenascin-C in human lung cancers, British J Cancer, 77:98-102 (1998).						
amy	28.	Mackie EJ, Molecules in focus: tenascin-C, Int J Biochem Cell Biol, 29:1133-1137 (1997).						
amn	29.	Mackie et al., Regulation of tenascin-C expression in Bone Cells by TGF-β, Bone, 22:301-307 (1998).						
amh	30.	Non-Hodgkin's Lymphoma Pathologic Classification Project, National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas, Cancer, 49:2112-2135 (1982).						
	31.	Reist et al., Human IgG2 constant region enha compared with its murine parent, Clinical Cat		oody 81C6				
anh	32.	Ribatti et al., Angiogenesis spectrum in the str immunohistochemical and ultrastructural stud	oma of B-cell non-Hodgkin's lyumphomas. ly, Eur J. Haematology, 56:45-53 (1996).	An				

EXAMINER

amtar

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation *EXAMINER if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO		U.S. Department of Commerce nt and Trademark Office	Attorney Docket Number 5405-252	Serial No. 10/008,062			
LIST	OF DO	CUMENTS CITED BY APPLICANT					
	P.E.	se several sheets Ondo Bs and	Applicants: David Rizzieri et al.				
lina o	7 2002	The same of the sa	Filing Date October 19, 2001	Group			
amh	,33'.``	Rizzieri et al., Markers of angiogenesis, factor patients with non-Hodgkin's lymphoma, Abs					
ame	34.	Sane et al., Vitronectin is a substrate for tran (1988).	isglutarninases. Biochem Biophys Res Com	mun., 157:115-20			
amh	35.	Schold et al., Distribution and dosimetry of languagestic glioma, Invest Radiol, 28:488-490		patients with			
amh	36.	Soini et al., Tenascin in reactive lymph node 1082 (1992).	s and in malignant lymphomas, Pathol Res	Pract., 188:1078-			
amh	37.	Takvorian et al., Treatment of relapsed non- marrow, UCLA Symposia on Molecular and					
amh	38.	Turner et al., Complexation of fibronectin with tissue transglutaminase, Biochemistry, 28: 628-635 (1989).					
	39.	Upchurch et al., Cellular transglutaminase h 23:795-800 (1987).	as affinity for extracellular matrix, In Vitro	Cell Dev Biol.,			
V	40.	Vacca et al., Expression of tenascin is related to histologic malignancy and angiogenesis in B-cell non-hodgkin's lymphomas, Leukemia and Lymphoma, 22:473-481 (1996).					
comb	41.	Walker et al., Interaction of human IgG chin requirements for antibody-mediated host cel					
1	42.	Zagzag et al., Tenascin-C expression by ang endothelial cells in vitro, Cancer Research.		by human brain			
,	43.	Zalutsky et al., A method for the radiohalog radioiodine, Appl. Radiat. Isot., 38:1051-10		hyroid uptake of			
V	44.	Zalutsky et al., Chimeric anti-tenascin antib murine parent, Nucl Med Biol, 23:449-458	-	mpared with its			
	-						
	 						
	 						
	+						
	1		ter en				

EXAMINER

INER Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant *EXAMINER

Şubstitute	e form 144	9A/PTO	
STATE	MENT B	DISCLOSUF Y APPLICAN	T _{JUN} 1 4 2002 3
Sheet	1	of	MADE

	Complete if Known
Application Number	10/008,062
Filing Date	October 19, 2001
First Named Inventor	David Rizzieri RECEIVED
Group Art Unit	1619 1642
Examiner Name	Unknown A.M. Harris 2012.D
Attorney Docket Number	5405.252 TECH CENTER 1600/29

				U.	S. PAT	TENT DOCUMENTS				
Examiner Cite No Initials*		o. U.S. Patent Do		U.S. Patent Document Number Kind Code (if known)		me of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	M/hara Clalauant	Passages Figures	
amh	1	5,6	5,624,659		Bigner et al.		4/29/1997			
				FOR	EIGN F	PATENT DOCUMENTS			- 2	
Examiner Initials*	Cite No.		Foreign Paten Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Line Where Relevant Passages or Releva Figures Appear		
Examiner	Cite		name of the author	r (in CAPITAL LE	TTERS)	PATENT LITERATURE), title of the article (when appropri	riate), title of the item (boo		Т	
Initials*	No.	serial, s	ymposium, catalo	g, etc.), date, pag	e(s), voli	ume-issue number(s), publisher,	city and/or country where	published 		
and	2	1	Chilosi, Marco, et al., Constitutive Expression of Tenascin in T-Dependent Zones of Human Lymphoid Tissues, American Journal of Pathology, Vol. 143, No. 5, pp. 1348-1355 (November 1993)							
amh	3	Rizzieri, D. A., et al., <i>Markers of Angiogenesis, Factor VIII and Tenascin, Correlate with Disease</i> Activity in Patients with Non-Hodgkin's Lymphoma, Abstract, Blood, Vol. 94, No. 10, Part 2, Supp. 1, page 4339 (15 November 1999)								
amh	4	Rizzieri, D.A., et al., <i>Radiolabeled anti-tenascin antibody for refractory non-Hodgkins lymphoma</i> , Abstract, Blood, Vol. 98, No. 11, Part 2, pp. 247b (16 November 2001)								
Mark	5	Intern	ational Search	Report, Inter	nation	al Application No. PCT/US	S01/46104 D4 D	1/2002		
								PY OF PAPERS		

Examiner Signature

Date Considered

6/28/2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.